Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Of the companies that reported their results last week, 18 beat analysts’ earnings forecasts, while 3 missed. On the revenue ...

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...

Merck & Co., Inc. (NYSE:MRK) is one of the top cheap pharmaceutical stocks to buy now. Goldman Sachs analyst Asad Haider ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair ...

In summary, Merck’s earnings call reflected a balanced outlook, with strong performances in key areas offset by significant challenges, particularly in China. The company’s forward-looking guidance ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...